9 Results for "

CDK1-IN-5

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "CDK1-IN-5" in MCE Product Catalog:

Cat. No.: HY-151409
CAS No.: 3032997-20-6
Target:  

CDK

Research Areas:  

Cancer

CDK1-IN-5 (10h) is a selective CDK1 inhibitor with IC50s of 42.19, 188.71 and 354.15 nM for CDK1, CDK2 and CDK5, respectively. CDK1-IN-5 inhibits growth of cancer cells by affecting cell cycle. CDK1-IN-5 can be used for the research of cancer .
loading...
    loading...
17
17 Publications Verification
Cat. No.: HY-10580
CAS No.: 667463-62-9
Purity:  99.31%
Synonyms: 6-BromoINdirubIN-3'-oxime; BIO; MLS 2052
Target:  

GSK-3 CDK Apoptosis

Research Areas:  

Cancer

GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18340
CAS No.: 294646-77-8
Synonyms: CR8, (R)-Isomer
Research Areas:  

Neurological Disease Cancer

(R)-CR8, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 induces apoptosis and has neuroprotective effect . (R)-CR8 acts as a molecular glue degrader that depletes cyclin K .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-18340A
CAS No.: 1786438-30-9
Synonyms: CR8, (R)-Isomer trihydrochloride
Research Areas:  

Neurological Disease Cancer

(R)-CR8 (CR8) trihydrochloride, a second-generation analog of Roscovitine, is a potent CDK1/2/5/7/9 inhibitor. (R)-CR8 trihydrochloride inhibits CDK1/cyclin B (IC50=0.09 μM), CDK2/cyclin A (0.072 μM), CDK2/cyclin E (0.041 μM), CDK5/p25 (0.11 μM), CDK7/cyclin H (1.1 μM), CDK9/cyclin T (0.18 μM) and CK1δ/ε (0.4 μM). (R)-CR8 trihydrochloride induces apoptosis and has neuroprotective effect . (R)-CR8 trihydrochloride acts as a molecular glue degrader that depletes cyclin K .
loading...
    loading...
Cat. No.: HY-14372
CAS No.: 1092443-55-4
Purity:  99.36%
Target:  

CDK

Research Areas:  

Cancer

BS-194 is an orally active, selective and potent CDK inhibitor. BS-194 inhibits CDK2, CDK1, CDK5, CDK7, CDK9 (IC50s: 3, 30, 30, 250, and 90 nM respectively). BS-194 potently inhibits cancer cells proliferation. BS-194 can be used in the research of cancers like breast cancer, colon cancer .
loading...
    loading...
Cat. No.: HY-N12625
CAS No.: 1364123-68-1
(R)-(+)-O-Demethylbuchenavianine is an inhibitor for Cyclin-dependent kinases (CDK). (R)-(+)-O-Demethylbuchenavianine inhibits CDK1, CDK5, glycogen synthase kinase-3 (GSK3), cdc2-like kinase (CLK1) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), with IC50s of 1.1, 0.95, >10, >10 and >10 μM, respectively .
loading...
    loading...
Cat. No.: HY-111931
CAS No.: 331467-05-1
Target:  

CDK GSK-3

Research Areas:  

Cancer

Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of CDK1, CDK5, and GSK-3β with IC50s of 5 nM, 7 nM, and 80 nM, respectively .
loading...
    loading...
Cat. No.: HY-111277
CAS No.: 856693-04-4
CEP-14513 is an ALK inhibitor with an IC50 of 4 nM. CEP-14513 also inhibits insulin receptor, VEGFR2, TIE2 and DLK kinases, but does not inhibit MET, IKKβ, or CDK1/2/5. CEP-14513 induces cancer cell apoptosis. CEP-14513 is applicable to research related to non-small cell lung cancer, anaplastic large cell lymphoma, inflammatory myofibroblastic tumor, and diffuse large B-cell lymphoma .
loading...
    loading...
Cat. No.: HY-10580R
CAS No.: 667463-62-9
Synonyms: 6-BromoINdirubIN-3'-oxime (Standard); BIO (Standard); MLS 2052 (Standard)
Research Areas:  

Cancer

GSK 3 Inhibitor IX (Standard) is the analytical standard of GSK 3 Inhibitor IX (HY-10580). This product is intended for research and analytical applications. GSK 3 Inhibitor IX (6-Bromoindirubin-3'-oxime; BIO) is a potent, selective, reversible and ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex with IC50s of 5 nM/320 nM/80 nM for (GSK-3α/β)/CDK1/CDK5, respectively.
loading...
    loading...